
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5133439/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. Gut, 2023, 72, 101-108.	6.1	8
2	Risk and Time Pattern of Recurrences After Local Endoscopic Resection of T1 Colorectal Cancer: A Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, e298-e314.	2.4	30
3	Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas. Clinical Gastroenterology and Hepatology, 2022, 20, e496-e507.	2.4	14
4	Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors. Digestive Endoscopy, 2022, 34, 163-170.	1.3	1
5	Continuous monitoring of colonoscopy performance in the Netherlands: first results of a nationwide registry. Endoscopy, 2022, 54, 488-495.	1.0	9
6	Lack of association between CDKN2A germline mutations and survival in patients with melanoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 87, 479-482.	0.6	6
7	Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. The Lancet Gastroenterology and Hepatology, 2022, 7, 60-68.	3.7	42
8	Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. European Journal of Cancer, 2022, 161, 38-43.	1.3	28
9	Hereditary pancreatic cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2022, 58-59, 101783.	1.0	14
10	Impact of surgical versus endoscopic management of complex nonmalignant polyps in a colorectal cancer screening program. Endoscopy, 2022, 54, 871-880.	1.0	4
11	First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210770.	1.4	4
12	Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing. PLoS ONE, 2022, 17, e0264067.	1.1	11
13	Systematic review: nonâ€endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome. Alimentary Pharmacology and Therapeutics, 2022, 55, 778-788.	1.9	6
14	The present and future of gastroenterology and hepatology: an international SWOT analysis (the) Tj ETQq0 0 0 r	gBŢ_/Overl	ock 10 Tf 50
15	Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study. The Lancet Gastroenterology and Hepatology, 2022, 7, 747-754.	3.7	40
16	Pancreatic Cancer Surveillance in Carriers of a Germline <i>CDKN2A</i> Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Journal of Clinical Oncology, 2022, 40, 3267-3277.	0.8	35

17	Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals. The Cochrane Library, 2022, 2022, .	1.5	13
18	Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic. PLoS ONE, 2022, 17, e0270223.	1.1	0

2

#	Article	IF	CITATIONS
19	Risk of recurrence after local resection of T1 rectal cancer: a meta-analysis with meta-regression. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 9156-9168.	1.3	6
20	PrefaceÂHereditary disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2022, , 101801.	1.0	0
21	Predictive Value of Endoscopic Features for a Complete Response After Chemoradiotherapy for Rectal Cancer. Annals of Surgery, 2021, 274, e541-e547.	2.1	31
22	Colonoscopy-Related Mortality in a Fecal Immunochemical Test–Based Colorectal Cancer Screening Program. Clinical Gastroenterology and Hepatology, 2021, 19, 1418-1425.	2.4	12
23	Endoscopically removed rectal NETs: a nationwide cohort study. International Journal of Colorectal Disease, 2021, 36, 535-541.	1.0	13
24	The Management of Peutz–Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline. Journal of Clinical Medicine, 2021, 10, 473.	1.0	65
25	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. BMC Gastroenterology, 2021, 21, 67.	0.8	2
26	Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer. International Journal of Molecular Sciences, 2021, 22, 2655.	1.8	14
27	Compliance with mismatch repair testing in pT1 colorectal cancer diagnosed before the age of 70 years. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 451-457.	1.4	Ο
28	When and How To Use Endoscopic Tattooing in the Colon: An International Delphi Agreement. Clinical Gastroenterology and Hepatology, 2021, 19, 1038-1050.	2.4	9
29	The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands Journal of Clinical Oncology, 2021, 39, 3531-3531.	0.8	Ο
30	Cutaneous squamous cell carcinoma is associated with Lynch syndrome: widening the spectrum of Lynch syndromeâ€associated tumours. British Journal of Dermatology, 2021, 185, 462-463.	1.4	6
31	Prospective experimental treatment of colorectal cancer patients based on organoid drug responses. ESMO Open, 2021, 6, 100103.	2.0	62
32	Can innovation in endoscopic therapy alter clinical outcomes in patients with familial adenomatous polyposis?. Endoscopy International Open, 2021, 09, E1445-E1446.	0.9	1
33	Colonoscopy and Its Complications are Inseparable of FIT-Based Screening. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	Ο
34	The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic. Preventive Medicine, 2021, 151, 106643.	1.6	32
35	The use of deep learning on endoscopic images to assess the response of rectal cancer after chemoradiation. Surgical Endoscopy and Other Interventional Techniques, 2021, , 1.	1.3	6
36	COVIDâ€19 and digestive health: Implications for prevention, care and the use of COVIDâ€19 vaccines in vulnerable patients. United European Gastroenterology Journal, 2021, 9, 1091-1095.	1.6	8

#	Article	IF	CITATIONS
37	Contact X-ray Brachytherapy for Older or Inoperable Rectal Cancer Patients: Short-Term Oncological and Functional Follow-Up. Cancers, 2021, 13, 6333.	1.7	8
38	Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut, 2020, 69, 112-121.	6.1	43
39	Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. Clinical Gastroenterology and Hepatology, 2020, 18, 1493-1500.	2.4	29
40	Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade. United European Gastroenterology Journal, 2020, 8, 59-67.	1.6	19
41	Familial Adenomatous Polyposis (FAP). , 2020, , 408-412.		0
42	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cutâ€off level on yield of screening. International Journal of Cancer, 2020, 147, 1098-1106.	2.3	29
43	Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. Journal of Medical Screening, 2020, 27, 68-76.	1.1	19
44	Quantification of Esophageal Tumor Motion and Investigation of Different Image-Guided Correction Strategies. Practical Radiation Oncology, 2020, 10, 84-92.	1.1	14
45	Interpretation and adherence to the updated risk-stratified guideline for colonoscopy surveillance after polypectomy – a nationwide survey. Endoscopy International Open, 2020, 08, E1405-E1413.	0.9	0
46	Transanal minimally invasive surgery (TAMIS) versus endoscopic submucosal dissection (ESD) for resection of non-pedunculated rectal lesions (TRIASSIC study): study protocol of a European multicenter randomised controlled trial. BMC Gastroenterology, 2020, 20, 225.	0.8	17
47	Low value of second-look endoscopy for detecting residual colorectal cancer after endoscopic removal. Gastrointestinal Endoscopy, 2020, 92, 166-172.	0.5	6
48	Dutch Gastrointestinal Endoscopy Audit: automated extraction of colonoscopy data for quality assessment and improvement. Gastrointestinal Endoscopy, 2020, 92, 154-162.e1.	0.5	16
49	Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. Journal of Clinical Medicine, 2020, 9, 190.	1.0	5
50	Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome. Gastroenterology, 2020, 158, 1326-1333.	0.6	60
51	Cumulative risk of skin cancer in patients with Li-Fraumeni syndrome. Familial Cancer, 2020, 19, 347-351.	0.9	6
52	Accurate surgical navigation with real-time tumor tracking in cancer surgery. Npj Precision Oncology, 2020, 4, 8.	2.3	16
53	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nature Medicine, 2020, 26, 566-576.	15.2	736
54	Substantial and sustained improvement of serrated polyp detection after a simple educational intervention: results from a prospective controlled trial. Gut, 2020, 69, 2150-2158.	6.1	19

#	Article	IF	CITATIONS
55	Gene expression profiles of esophageal squamous cell cancers in Hodgkin lymphoma survivors versus sporadic cases. PLoS ONE, 2020, 15, e0243178.	1.1	2
56	RADIATION DOSE IS NOT ASSOCIATED WITH THE SEVERITY OF ANASTOMOTIC STENOSIS AFTER NEOADJUVANT CHEMORADIOTHERAPY AND SURGICAL RESECTION IN ESOPHAGEAL AND GASTROESOPHAGEAL JUNCTION CARCINOMA. , 2020, 52, .		0
57	CD31-positive microvessel density within adenomas of Lynch Syndrome patients is similar compared to adenomas of non-Lynch patients. Endoscopy International Open, 2019, 07, E701-E707.	0.9	3
58	Yield of Surveillance Colonoscopies 1 Year After Curative Surgical Colorectal Cancer Resections. Clinical Gastroenterology and Hepatology, 2019, 17, 2285-2293.	2.4	11
59	Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2019, 51, 877-895.	1.0	157
60	Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Science Translational Medicine, 2019, 11, .	5.8	451
61	Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2019, 51, 1082-1093.	1.0	80
62	Su1727 LOW INCIDENCE OF ADVANCED NEOPLASIA IN SERRATED POLYPOSIS SYNDROME AFTER (SUB)TOTAL COLECTOMY - RESULTS FROM A 5-YEAR INTERNATIONAL PROSPECTIVE COHORT STUDY. Gastrointestinal Endoscopy, 2019, 89, AB396-AB397.	0.5	0
63	EUS-guided fiducial marker placement for radiotherapy in rectal cancer: feasibility of two placement strategies and four fiducial types. Endoscopy International Open, 2019, 07, E1357-E1364.	0.9	10
64	Feasibility of Gold Fiducial Markers as a Surrogate for Gross Tumor Volume Position in Image-Guided Radiation Therapy of Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1151-1159.	0.4	2
65	Effects of Family History on Relative and Absolute Risks for Colorectal Cancer: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 2657-2667.e9.	2.4	42
66	MRI visibility of gold fiducial markers for image-guided radiotherapy of rectal cancer. Radiotherapy and Oncology, 2019, 132, 93-99.	0.3	15
67	481 INDIVIDUALIZED SURVEILLANCE FOR SERRATED POLYPOSIS SYNDROME: RESULTS FROM A PROSPECTIVE 5-YEAR INTERNATIONAL COHORT STUDY. Gastrointestinal Endoscopy, 2019, 89, AB88-AB89.	0.5	0
68	Somatic mosaicism by a de novo <i> MLH1</i> mutation as a cause of Lynch syndrome. Molecular Genetics & Genomic Medicine, 2019, 7, e00699.	0.6	20
69	Low Incidence of Advanced Neoplasia in Serrated Polyposis Syndrome After (Sub)total Colectomy: Results of a 5-Year International Prospective Cohort Study. American Journal of Gastroenterology, 2019, 114, 1512-1519.	0.2	2
70	High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer, 2019, 125, 990-999.	2.0	23
71	Overall and diseaseâ€specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer. Cancer Medicine, 2019, 8, 190-199.	1.3	5
72	A squamous cell carcinoma in a young woman with Lynch syndrome. Familial Cancer, 2019, 18, 193-196.	0.9	7

#	Article	IF	CITATIONS
73	Optical diagnosis expanded to small polyps: post-hoc analysis of diagnostic performance in a prospective multicenter study. Endoscopy, 2019, 51, 244-252.	1.0	11
74	Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program. Clinical Chemistry, 2019, 65, 419-426.	1.5	7
75	Quality assurance of colonoscopy within the Dutch national colorectal cancer screening program. Gastrointestinal Endoscopy, 2019, 89, 1-13.	0.5	48
76	Nutritional and vitamin status in patients with neuroendocrine neoplasms. World Journal of Gastroenterology, 2019, 25, 1171-1184.	1.4	20
77	Rapid on-site evaluation during endoscopic ultrasoundguided fine-needle aspiration of lymph nodes does not increase diagnostic yield: A randomized, multicenter trial. American Journal of Gastroenterology, 2018, 113, 677-685.	0.2	33
78	Cumulative risk of skin tumours in patients with Lynch syndrome. British Journal of Dermatology, 2018, 179, 522-523.	1.4	9
79	Effects of Training and Feedback on Accuracy of Predicting Rectosigmoid Neoplastic Lesions and Selection of Surveillance Intervals by Endoscopists Performing Optical Diagnosis of Diminutive Polyps. Gastroenterology, 2018, 154, 1682-1693.e1.	0.6	38
80	Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned. Oncologist, 2018, 23, 399-e33.	1.9	23
81	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open, 2018, 3, e000278.	2.0	197
82	Volume of surgery for benign colorectal polyps in the last 11 years. Gastrointestinal Endoscopy, 2018, 87, 552-561.e1.	0.5	44
83	Endoscopic detection rate of sessile serrated lesions in Lynch syndrome patients is comparable with an age- and gender-matched control population: case-control study with expert pathology review. Gastrointestinal Endoscopy, 2018, 87, 1289-1296.	0.5	18
84	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Gut, 2018, 67, 447-455.	6.1	27
85	Stage distribution of screen-detected colorectal cancers in the Netherlands. Gut, 2018, 67, 1745-1746.	6.1	37
86	Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer. Annals of Oncology, 2018, 29, viii731.	0.6	44
87	EP-2115: MRI visibility of gold fiducial markers for image-guided radiotherapy for rectal cancer. Radiotherapy and Oncology, 2018, 127, S1163-S1164.	0.3	0
88	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell, 2018, 174, 1586-1598.e12.	13.5	644
89	Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. Gut, 2017, 66, 118-123.	6.1	24
90	Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: a multicentre cohort analysis. Gut, 2017, 66, 278-284.	6.1	94

#	Article	IF	CITATIONS
91	Gastrointestinal diseases and their oro-dental manifestations: Part 4: Peutz-Jeghers syndrome. British Dental Journal, 2017, 222, 214-217.	0.3	12
92	Small-bowel Surveillance in Patients With Peutz-Jeghers Syndrome. Journal of Clinical Gastroenterology, 2017, 51, e27-e33.	1.1	24
93	Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors. British Journal of Cancer, 2017, 117, 306-314.	2.9	26
94	Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1328-1336.	1.1	14
95	Correlation between symptoms, endoscopic features and treatment response in immunotherapy induced colitis. European Journal of Cancer, 2017, 72, S159.	1.3	0
96	Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Diseases of the Colon and Rectum, 2017, 60, 477-487.	0.7	15
97	Incidence of small bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Endoscopy International Open, 2017, 05, E622-E626.	0.9	16
98	The Prevalence of Sessile Serrated Polyps in Patients with Lynch Syndrome Undergoing Surveillance is Comparable to Patients Undergoing Colonoscopy for Symptoms. Gastroenterology, 2017, 152, S554.	0.6	0
99	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer, 2017, 17, 112.	1.1	8
100	Real-Time Monitoring of Results During First Year ofÂDutchÂColorectal Cancer Screening Program andÂOptimizationÂbyÂAltering Fecal Immunochemical TestÂCut-OffÂLevels. Gastroenterology, 2017, 152, 767-775.e2.	0.6	179
101	Nivolumab, ipilimumab and COX2-inhibition in early stage colon cancer. Annals of Oncology, 2017, 28, v207.	0.6	0
102	Long-term survival of gastrointestinal cancer diagnosed in Hodgkin lymphoma survivors Journal of Clinical Oncology, 2017, 35, 40-40.	0.8	0
103	Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme. Alimentary Pharmacology and Therapeutics, 2016, 44, 88-96.	1.9	8
104	Sa1219 Impact of Mortality From Surgical Adenoma Removal on the Effectiveness of Colorectal Cancer Screening. Gastroenterology, 2016, 150, S253-S254.	0.6	0
105	Mo1691 CT-Colonography Versus Colonoscopy for Detection of High-Risk Sessile Serrated Polyps. Gastroenterology, 2016, 150, S752-S753.	0.6	0
106	Mo1706 Optimizing Screening Programs by Real-Time Monitoring: Outcomes of the National Colorectal Cancer FIT-Based Screening Program of the Netherlands. Gastroenterology, 2016, 150, S757-S758.	0.6	0
107	Su1258 Small-Bowel Surveillance in Patients With Peutz-Jeghers Syndrome: Comparing Magnetic Resonance Enteroclysis and Double Balloon Enteroscopy Gastrointestinal Endoscopy, 2016, 83, AB330.	0.5	0
108	Mo1156 Meta-Analysis on Guaiac-Based Fecal Occult Blood Tests Versus Fecal Immunochemical Tests for Colorectal Cancer Screening in Average-Risk Individuals. Gastroenterology, 2016, 150, S653.	0.6	0

#	Article	IF	CITATIONS
109	CT-Colonography vs. Colonoscopy for Detection of High-Risk Sessile Serrated Polyps. American Journal of Gastroenterology, 2016, 111, 516-522.	0.2	79
110	Smoking status informs about the risk of advanced serrated polyps in a screening population. Endoscopy International Open, 2016, 04, E73-E78.	0.9	15
111	Quantification of Esophageal Tumor Motion and Recommendations on Setup Verification Strategy During Image Guided Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E638-E639.	0.4	0
112	SP-0197: Consequences of bowel cancer screening programmes. Radiotherapy and Oncology, 2016, 119, S91.	0.3	0
113	A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. BMC Cancer, 2016, 16, 513.	1.1	76
114	A case series of intestinal adenomatous polyposis of unidentified etiology; a late effect of irradiation?. BMC Cancer, 2016, 16, 862.	1.1	7
115	Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genetics in Medicine, 2016, 18, 966-973.	1.1	42
116	Different modalities for colorectal cancer screening: experiences in The Netherlands so far. Colorectal Cancer, 2016, 5, 9-19.	0.8	2
117	Crizotinib-induced fatal fulminant liver failure. Lung Cancer, 2016, 93, 17-19.	0.9	22
118	Genetic testing for Lynch syndrome: family communication and motivation. Familial Cancer, 2016, 15, 63-73.	0.9	42
119	Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps. Gut, 2016, 65, 963-970.	6.1	208
120	Second-Look Colonoscopies and the Impact on Capacity in FIT-Based Colorectal Cancer Screening. American Journal of Gastroenterology, 2015, 110, 1072-1077.	0.2	7
121	Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia. Clinical Gastroenterology and Hepatology, 2015, 13, 1464-1471.e4.	2.4	34
122	Metachronous colorectal cancer: Is it all about colonoscopy quality?. Gastrointestinal Endoscopy, 2015, 82, 334-336.	0.5	1
123	Mo1979 Offering Colonoscopy to Participants With a Negative FIT and a First Degree Relative With CRC Increases the Detection of Advanced Neoplasia in a Screening Program. Gastroenterology, 2015, 148, S-757.	0.6	Ο
124	Prevalence of small-bowel neoplasia in Lynch syndrome assessed by video capsule endoscopy. Gut, 2015, 64, 1578-1583.	6.1	47
125	Sa1559 Development and Validation of the WASP-Classification System for Optical Diagnosis of Adenomas, Hyperplastic Polyps and Sessile Serrated Adenomas/Polyps. Gastrointestinal Endoscopy, 2015, 81, AB260-AB261.	0.5	0
126	Polyp Morphology: An Interobserver Evaluation for the Paris Classification Among International Experts. American Journal of Gastroenterology, 2015, 110, 180-187.	0.2	86

#	Article	IF	CITATIONS
127	Narrow-band imaging for the detection of polyps in patients with serrated polyposis syndrome: a multicenter, randomized, back-to-back trial. Gastrointestinal Endoscopy, 2015, 81, 531-538.	0.5	37
128	Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy. Gut, 2014, 63, 466-471.	6.1	89
129	Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy. Endoscopy, 2014, 46, 219-224.	1.0	106
130	Su1234 A Systematic Review on Diagnostic Test Accuracy of Fecal Immunochemical Tests for Colorectal Cancer Screening. Gastroenterology, 2014, 146, S-409-S-410.	0.6	0
131	Comparing Quality, Safety, and Costs of Colonoscopies Performed by Nurse vs Physician Trainees. Clinical Gastroenterology and Hepatology, 2014, 12, 470-477.	2.4	28
132	Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Annals of Oncology, 2014, 25, 864-869.	0.6	41
133	Somatic aberrations of mismatch repair genes as a cause of microsatelliteâ€unstable cancers. Journal of Pathology, 2014, 234, 548-559.	2.1	134
134	Attendance and Yield Over Three Rounds of Population-Based Fecal Immunochemical Test Screening. American Journal of Gastroenterology, 2014, 109, 1257-1264.	0.2	100
135	Limited diagnostic value of microsatellite instability associated pathology features in colorectal cancer. Familial Cancer, 2014, 13, 351-359.	0.9	3
136	Informed decision-making in colorectal cancer screening using colonoscopy or CT-colonography. Patient Education and Counseling, 2013, 91, 318-325.	1.0	16
137	What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?. European Journal of Cancer, 2013, 49, 2321-2330.	1.3	57
138	Colorectal cancer risk factors in the detection of advanced adenoma and colorectal cancer. Cancer Epidemiology, 2013, 37, 278-283.	0.8	45
139	Differences in proximal serrated polyp detection among endoscopists are associated with variability in withdrawal time. Gastrointestinal Endoscopy, 2013, 77, 617-623.	0.5	122
140	The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies?. Lancet Oncology, The, 2013, 14, e38-e46.	5.1	21
141	Extracolonic cancer risk in patients with serrated polyposis syndrome and their first-degree relatives. Familial Cancer, 2013, 12, 669-673.	0.9	26
142	Time requirements and health effects of participation in colorectal cancer screening with colonoscopy or computed tomography colonography in a randomized controlled trial. Endoscopy, 2013, 45, 182-188.	1.0	9
143	Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut, 2013, 62, 727-734.	6.1	68
144	Optimal resource allocation in colonoscopy: timing of follow-up colonoscopies in relation to adenoma detection rates. Endoscopy, 2013, 45, 545-552.	1.0	18

#	Article	IF	CITATIONS
145	Identification of molecular alterations in gastrointestinal carcinomas and dysplastic hamartomas in Peutz-Jeghers syndrome. Carcinogenesis, 2013, 34, 1611-1619.	1.3	26
146	Risk factors for false positive and for false negative test results in screening with fecal occult blood testing. International Journal of Cancer, 2013, 133, 2408-2414.	2.3	42
147	Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening. Gut, 2013, 62, 409-415.	6.1	112
148	Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. Journal of Medical Genetics, 2013, 50, 59-64.	1.5	94
149	Second Primary Cancers in Subsites of Colon and Rectum in Patients With Previous Colorectal Cancer. Diseases of the Colon and Rectum, 2013, 56, 158-168.	0.7	37
150	The Appropriateness of Surveillance Colonoscopy Intervals after Polypectomy. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 33-38.	1.8	26
151	Peutz–Jeghers syndrome and family planning: the attitude towards prenatal diagnosis and pre-implantation genetic diagnosis. European Journal of Human Genetics, 2012, 20, 236-239.	1.4	14
152	The NordICC Study: Rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy, 2012, 44, 695-702.	1.0	149
153	Benchmarking patient experiences in colonoscopy using the Global Rating Scale. Endoscopy, 2012, 44, 462-472.	1.0	41
154	Quality assurance in the endoscopy unit: the view of endoscopy personnel. Frontline Gastroenterology, 2012, 3, 115-120.	0.9	1
155	Authors' response: Figure 1. Gut, 2012, 61, 322.3-323.	6.1	0
156	Nurse endoscopists perform colonoscopies according to the international standard and with high patient satisfaction. Endoscopy, 2012, 44, 1127-1132.	1.0	33
157	Adenoma detection with cap-assisted colonoscopy versus regular colonoscopy: a randomised controlled trial. Gut, 2012, 61, 1426-1434.	6.1	102
158	Burden of colonoscopy compared to non-cathartic CT-colonography in a colorectal cancer screening programme: randomised controlled trial. Gut, 2012, 61, 1552-1559.	6.1	76
159	Immunochemical Fecal Occult Blood Testing Is Equally Sensitive for Proximal and Distal Advanced Neoplasia. American Journal of Gastroenterology, 2012, 107, 1570-1578.	0.2	173
160	Are Fecal Immunochemical Test Characteristics Influenced by Sample Return Time? A Population-Based Colorectal Cancer Screening Trial. American Journal of Gastroenterology, 2012, 107, 99-107.	0.2	51
161	Face-to-face vs telephone pre-colonoscopy consultation in colorectal cancer screening; a randomised trial. British Journal of Cancer, 2012, 107, 1051-1058.	2.9	10
162	The Incidence of 30-Day Adverse Events After Colonoscopy Among Outpatients in the Netherlands. American Journal of Gastroenterology, 2012, 107, 878-884.	0.2	22

#	Article	IF	CITATIONS
163	Quality of life in participants of a CRC screening program. British Journal of Cancer, 2012, 107, 1295-1301.	2.9	21
164	The Incidence and Risk Factors of Metachronous Colorectal Cancer. Diseases of the Colon and Rectum, 2012, 55, 522-531.	0.7	90
165	Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncology, The, 2012, 13, 55-64.	5.1	325
166	A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 653-660.	0.4	22
167	Awareness of Surveillance Recommendations Among Patients With Colorectal Adenomas. Clinical Gastroenterology and Hepatology, 2012, 10, 405-411.	2.4	15
168	Tu1730 Cost-Effectiveness of Colonoscopies Performed by Nurse Endoscopists. Gastrointestinal Endoscopy, 2012, 75, AB503-AB504.	0.5	1
169	Small bowel endoscopy and Peutz-Jeghers syndrome. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 263-278.	1.0	23
170	The Global Rating Scale in clinical practice: A comprehensive quality assurance programme for endoscopy departments. Digestive and Liver Disease, 2012, 44, 919-924.	0.4	32
171	Quality evaluation of colonoscopy reporting and colonoscopy performance in daily clinical practice. Gastrointestinal Endoscopy, 2012, 75, 98-106.	0.5	105
172	Su1297 Quality Assessment of Colonoscopies Performed by Nurse and Physician Endoscopists Reveals High Safety and Good Quality in Nurse Endoscopists. Gastrointestinal Endoscopy, 2012, 75, AB283-AB284.	0.5	0
173	Reasons for Participation and Nonparticipation in Colorectal Cancer Screening: A Randomized Trial of Colonoscopy and CT Colonography. American Journal of Gastroenterology, 2012, 107, 1777-1783.	0.2	46
174	Awareness of Postpolypectomy Surveillance Guidelines: A Nationwide Survey of Colonoscopists in Canada. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 79-84.	1.8	21
175	Yield of routine molecular analyses in colorectal cancer patients ≤0 years to detect underlying Lynch syndrome. Journal of Pathology, 2012, 226, 764-774.	2.1	62
176	Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer â‰\$70 years. Gynecologic Oncology, 2012, 125, 414-420.	0.6	115
177	PTEN in colorectal cancer: a report on two Cowden syndrome patients. Clinical Genetics, 2012, 81, 555-562.	1.0	13
178	Uptake of faecal immunochemical test screening among nonparticipants in a flexible sigmoidoscopy screening programme. International Journal of Cancer, 2012, 130, 2096-2102.	2.3	28
179	Diagnostic Yield Improves With Collection of 2 Samples in Fecal Immunochemical Test Screening Without Affecting Attendance. Clinical Gastroenterology and Hepatology, 2011, 9, 333-339.	2.4	81
180	Attitude of Endoscopists and Endoscopy Personnel Towards Quality Assurance. Gastroenterology, 2011. 140. S-562-S-563.	0.6	0

#	Article	IF	CITATIONS
181	Evaluation of a Quality Assurance Program for Endoscopy Services in the Netherlands. Gastroenterology, 2011, 140, S-558-S-559.	0.6	1
182	Family Communication in Lynch Syndrome Families: Experiences With the Family-Linked Approach. Gastroenterology, 2011, 140, S-259.	0.6	0
183	Histological Features Associated With Lymph Node Metastases in T1 Colorectal Cancer. Gastroenterology, 2011, 140, S-340.	0.6	0
184	Cost-effectiveness Analysis of a Quantitative Immunochemical Test for Colorectal Cancer Screening. Gastroenterology, 2011, 141, 1648-1655.e1.	0.6	111
185	Sensitivity and Specificity of Fit in an Average Risk Screening Population. Gastroenterology, 2011, 140, S-408.	0.6	0
186	Opinion of gastroenterologists towards quality assurance in endoscopy. Digestive and Liver Disease, 2011, 43, 215-219.	0.4	4
187	A Randomized Controlled Trial Comparing Participation and Diagnostic Yield in Colonoscopy and CT-Colonography for Population Based Colorectal Cancer Screening. Gastroenterology, 2011, 140, S-74.	0.6	0
188	Reasons to Decline Colonoscopy or CT Colonography Screening: A Randomized Controlled Trial. Gastroenterology, 2011, 140, S-408-S-409.	0.6	0
189	Can an Individual Risk Profile for CRC Be Used as Triage Test in CRC Screening. Gastroenterology, 2011, 140, S-414.	0.6	0
190	Randomized Trial Comparing Pre-Colonoscopy Consultation by Telephone Versus Face-to-Face Consultation at the Outpatient Clinic in a Population Based Colorectal Cancer Screening Program. Gastroenterology, 2011, 140, S-408.	0.6	0
191	The True Unit Costs of Colonoscopy in a Dedicated Screening Setting. Gastroenterology, 2011, 140, S-412.	0.6	0
192	The Diagnostic Value of Risk Factors in Population Screening for Colorectal Cancer. Gastroenterology, 2011, 140, S-410.	0.6	0
193	Challenges and Pitfalls in Screening for Lynch Syndrome by Molecular Tumor Tissue Analysis. Gastroenterology, 2011, 140, S-352-S-353.	0.6	0
194	Attendance and Diagnostic Yield of Repeated Fecal Immunochemical Test Screening With Intervals of 1, 2, or 3 Years: A Comparative Population-Based Colorectal Cancer Screening Trial. Gastroenterology, 2011, 140, S-405.	0.6	1
195	Perceived Burden of Screening by Colonoscopy or CT-Colonography in the Detection of Advanced Neoplasia: A Randomized Controlled Trial. Gastroenterology, 2011, 140, S-409.	0.6	0
196	Prevalence and prognosis of synchronous colorectal cancer: A Dutch population-based study. Cancer Epidemiology, 2011, 35, 442-447.	0.8	84
197	Influence of Antiflatulent Dietary Advice on Intrafraction Motion for Prostate Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, e401-e406.	0.4	26
198	P2-160 Right-side shifting of second colorectal cancer-implications for aetiology and clinical relevance. Journal of Epidemiology and Community Health, 2011, 65, A265-A265.	2.0	0

#	Article	IF	CITATIONS
199	Pitfalls in molecular analysis for mismatch repair deficiency in a family with biallelic pms2 germline mutations. Clinical Genetics, 2011, 80, 558-565.	1.0	25
200	Inter-observer variation in the histological diagnosis of polyps in colorectal cancer screening. Histopathology, 2011, 58, 974-981.	1.6	46
201	Advance notification letters increase adherence in colorectal cancer screening: A population-based randomized trial. Preventive Medicine, 2011, 52, 448-451.	1.6	48
202	How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?. Cancer, 2011, 117, 4166-4174.	2.0	33
203	Overview of the quality assurance movement in health care. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 337-347.	1.0	35
204	Systematic literature review and pooled analyses of risk factors for finding adenomas at surveillance colonoscopy. Endoscopy, 2011, 43, 560-574.	1.0	63
205	Fecal Occult Blood Testing When Colonoscopy Capacity is Limited. Journal of the National Cancer Institute, 2011, 103, 1741-1751.	3.0	65
206	High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut, 2011, 60, 141-147.	6.1	165
207	High Cumulative Risk of Intussusception in Patients With Peutz–Jeghers Syndrome: Time to Update Surveillance Guidelines?. American Journal of Gastroenterology, 2011, 106, 940-945.	0.2	138
208	Exposure to colorectal examinations before a colorectal cancer diagnosis: a case–control study. European Journal of Gastroenterology and Hepatology, 2010, 22, 437-443.	0.8	47
209	Colorectal Cancer in Post-Liver Transplant Recipients. Diseases of the Colon and Rectum, 2010, 53, 817-821.	0.7	13
210	CT colonography with limited bowel preparation for the detection of colorectal neoplasia in an FOBT positive screening population. Abdominal Imaging, 2010, 35, 661-668.	2.0	34
211	Performance improvements of stool-based screening tests. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 479-492.	1.0	46
212	Risk of Colorectal Carcinoma in Post-Liver Transplant Patients: A Systematic Review and Meta-analysis. American Journal of Transplantation, 2010, 10, 868-876.	2.6	70
213	A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. Journal of Cellular and Molecular Medicine, 2010, 14, 181-197.	1.6	62
214	Study protocol: population screening for colorectal cancer by colonoscopy or CT colonography: a randomized controlled trial. BMC Gastroenterology, 2010, 10, 47.	0.8	56
215	Labeled versus Unlabeled Discrete Choice Experiments in Health Economics: An Application to Colorectal Cancer Screening. Value in Health, 2010, 13, 315-323.	0.1	156
216	Preferences for colorectal cancer screening strategies: a discrete choice experiment. British Journal of Cancer, 2010, 102, 972-980.	2.9	77

#	Article	IF	CITATIONS
217	Quality of life and psychological distress in patients with Peutz–Jeghers syndrome. Clinical Genetics, 2010, 78, 219-226.	1.0	10
218	A Prospective Audit of Patient Experiences in Colonoscopy Using the Global Rating Scale: A Cohort of 1187 Patients. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 607-613.	1.8	35
219	A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects. Gut, 2010, 59, 785-793.	6.1	66
220	Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut, 2010, 59, 62-68.	6.1	411
221	On the advent of MSI testing of all colorectal cancers and a substantial part of other Lynch syndrome-related neoplasms. Expert Review of Molecular Diagnostics, 2010, 10, 381-384.	1.5	5
222	Endoscopic therapy of small-bowel polyps by double-balloon enteroscopy in patients with Peutz-Jeghers syndrome. Gastrointestinal Endoscopy, 2010, 71, 768-773.	0.5	79
223	683e: Nurse Endoscopists Performing Colonoscopy: A Prospective Study on Quality and Patient Experiences. Gastrointestinal Endoscopy, 2010, 71, AB130.	0.5	1
224	S1403: Assessment of Colonoscopy Reporting in a Multicenter Study Using the ASGE Quality Assurance Task Force Guidelines. Gastrointestinal Endoscopy, 2010, 71, AB152.	0.5	1
225	M1427: Blinded Peer Review to Measure Colonoscopy Performance of an Individual Endoscopist. Gastrointestinal Endoscopy, 2010, 71, AB218.	0.5	0
226	M1430: The Opinion of Gastroenterologists Towards Quality Assurance in Endoscopy. Gastrointestinal Endoscopy, 2010, 71, AB219.	0.5	0
227	M1529: Risk Factors of Adenoma Recurrence At Surveillance Colonoscopy: A Systematic Literature Review and Pooled Analysis. Gastrointestinal Endoscopy, 2010, 71, AB246.	0.5	0
228	S1145 Costs of Guaiac Versus Immunochemical Fecal Occult Blood Testing Within a Randomized Population-Based Colorectal Cancer Screening Trial. Gastroenterology, 2010, 138, S-189-S-190.	0.6	2
229	Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study. Gut, 2010, 59, 1094-1100.	6.1	210
230	High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations. American Journal of Gastroenterology, 2010, 105, 1258-1264.	0.2	426
231	What determines individuals' preferences for colorectal cancer screening programmes? A discrete choice experiment. European Journal of Cancer, 2010, 46, 150-159.	1.3	65
232	Screening for colorectal cancer: Comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy. European Journal of Cancer, 2010, 46, 2059-2066.	1.3	50
233	Mutation prediction models in Lynch syndrome: evaluation in a clinical genetic setting. Journal of Medical Genetics, 2009, 46, 745-751.	1.5	12
234	The views of gastroenterologists about the role of nurse endoscopists, especially in colorectal cancer screening. Alimentary Pharmacology and Therapeutics, 2009, 29, 892-897.	1.9	9

2131Screening for colorectal cancer, random comparison of guide, and immunochemical faceal occult2.92.45226Classifying Admomstrate and Non-Admomstrate Colorectal Polys. Cancer, 2009, 100, 1105 1110.0.53227Right analyses for screening sigmoidoscopy based on a colorectal cancer (GC) population.0.60228Right analyses for screening sigmoidoscopy based on a colorectal cancer (GC) population.0.60229Right analyses for screening sigmoidoscopy based on a colorectal cancer (GC) population.0.60230Concer rais in MLH1, MSH2 and MSH6 mutation canters different risk profiles may influence clinical0.60240Coloroscopy Peer Review Utilizing Automated Video Capture. American Journal of Castroenterology, 2009, 144, 600-604.0.70241Perface. Balliere's Best Practice and Research in Clinical Castroenterology, 2009, 22, 207-205.1.03243Coloroscopy Oger Review Utilizing Automated Video Capture. American Journal of Castroenterology, 2008, 22, 207-205.1.03244Coloroscopy Oger Review Utilizing Automated Video Capture. American and Research in0.03245Coloroscopy, 2009, 67, ASD23.0.200246Coloroscopy, 2009, 67, ASD3.0.300247Coloroscopy, 2008, 67, ASD3.0.300248Chineal Gastroenterology, 2008, 67, ASD3.0.130249Applet Incodence of MSH6 mutations in Amsterdam eiteria Unegative families tested in a diagnostic.0.22244Ahigh Incodence	#	Article	IF	CITATIONS
236 Classifying Adenomatous and Non-Adenomatous Colorectal Polyps. Gastrointestinal Endoscopy, 2009, 0.5 3 237 Rek analyses for screening sigmoidoscopy based on a colorectal cancer (CRC) population. 0.6 6 238 Linderutilization of microsatellite instability analysis in colorectal cancer patients at high risk for 0.6 27 238 Linderutilization of microsatellite instability analysis in colorectal cancer patients at high risk for 0.6 27 239 Cancer risk in ML11, MSH2 and MSH6 mutation carries: different risk profiles may influence clinical management. Hereditary Cancer in Clinical Practice, 2009, 7, 17. 0.6 67 240 Colonoscopy Peer Review Utilizing Automated Video Capture. American Journal of Gastroenterology, 2008, 22, 207-208. 1.0 3 241 Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 207-208. 1.0 3 242 Epidemiology of acute upper gastrointestinal bleeding. Bailliere's Best Practice and Research in 1.0 314 243 Optimal Screening Intervals for Individuals with a Family History of Colorectal Cancer. 0.5 0 244 Epidemiology of ACU 2008, 57, 1339-1340. 1.1 15 245 A high incidence of MSH6 mutations in Amsterdam criteria Il-negative families tested in a diagnostic 0.	235		2.9	245
237 Scandinavian Journal of Gaströenterology, 2009, 44, 205-210. 0.00 0 238 Underutilization of microsatellite instability analysis in colorectal cancer patients at high risk for Lynch syndrome. Scandinavian Journal of Gaströenterology, 2009, 44, 600-604. 0.6 27 239 Cancer risk in MLH1, MSH2 and MSH6 mutation carriers, different risk profiles may influence clinical 0.6 57 240 Colonoscopy Peer Review Utilizing Automated Video Capture. American Journal of Gaströenterology, 0.2 2 241 Preface. Bailliser's Best Practice and Research in Clinical Caströenterology, 2008, 22, 207-208. 1.0 3 242 Epidemiology of acute upper gastrointestinal bleeding. Baillier's Best Practice and Research in 1.0 314 243 Cohniel Caströenterology, 2008, 67, A8235. 0.5 0 244 Crohn's-like enterocolitis associated with mycophenolic acid treatment. Cut, 2008, 57, 1330-1330. 6.1 15 244 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. 0.2 21 245 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. 0.2 21 246 Angein numers and colonoscopy. Endoscopy, 2008, 40, 843-848. 1.0 4	236	Classifying Adenomatous and Non-Adenomatous Colorectal Polyps. Gastrointestinal Endoscopy, 2009,	0.5	3
218 Lynch syndrome. Scandinavian Journal of Gastroenterology, 2009, 44, 600-604. 0.6 27 239 Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical 0.6 57 240 Colonoscopy Peer Review Utilizing Automated Video Capture. American Journal of Gastroenterology, 0.2 2 241 Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 207-208. 1.0 3 242 Epidemiology of acute upper gastrointestinal bleeding. Bailliere's Best Practice and Research in 1.0 314 243 Optimal Screening Intervals for Individuals with a Family History of Colorectal Cancer. 0.5 0 244 Crohn's like enterocolitis associated with mycophenolic acid treatment. Cut, 2008, 57, 1330-1330. 6.1 15 245 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. 0.2 21 246 Colon tumors and colonoscopy. Endoscopy, 2008, 103, 1505-1509. 0.4 4 247 Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848. 1.0 4 248 A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or rizetiment for Colorectal Cancer, Journal of Castroenterology, 2007, 42, 66-71. 32 249 </td <td>237</td> <td></td> <td>0.6</td> <td>6</td>	237		0.6	6
239 management. Hereditary Cancer in Clinical Practice, 2009, 7, 17. 0.0 57 240 Colonoscopy Peer Review Utilizing Automated Video Capture. American Journal of Gastroenterology, 0.2 2 241 Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 207-208. 1.0 3 242 Epidemiology of acute upper gastrointestinal bleeding. Bailliere's Best Practice and Research in 1.0 314 243 Celonis Castroenterology, 2008, 22, 209-224. 0.5 0 244 Crohn's-like enterocolitis associated with a Family History of Colorectal Cancer. 0.5 0 244 Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut, 2008, 57, 1330-1330. 6.1 15 245 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. 0.2 21 246 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. 0.2 21 247 Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848. 1.0 4 248 Anationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492. 1.1 32 247 Attendance at s	238		0.6	27
240 2009, 104, 5522. 0 0.2 2 241 Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 207-208. 1.0 3 242 Epidemiology of acute upper gastrointestinal bleeding. Bailliere's Best Practice and Research in 1.0 314 243 Central Gastroenterology, 2008, 22, 209-224. 0.5 0 244 Coptimal Screening Intervals for Individuals with a Family History of Colorectal Cancer. 0.5 0 244 Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut, 2008, 57, 1330-1330. 6.1 15 245 Ahigh incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut, 2008, 57, 1539-1544. 0.2 21 246 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. 0.2 21 247 Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848. 1.0 4 248 A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Castroenterology, 2008, 42, 487-492. 1.1 32 247 Doin tumors and colonoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Castroenterology, 2007, 42, 66-71. 0.6 16	239		0.6	57
242 Epidemiology of acute upper gastrointestinal bleeding. Bailliere's Best Practice and Research in 1.0 314 243 Optimal Screening Intervals for Individuals with a Family History of Colorectal Cancer. 0.5 0 244 Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut, 2008, 57, 1330-1330. 6.1 15 245 Ahigh incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Cut, 2008, 57, 1539-1544. 6.1 33 246 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. 0.2 21 247 Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848. 1.0 4 248 A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Castroenterology, 2008, 42, 487-492. 1.1 32 249 Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 66-71. 0.6 16 250 Tumor pyruvete kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance prosport, 9. 0.8 38 250 Tumor purvete kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance performance performance performance perforolorectal cancer. European Journal of Gastroe	240		0.2	2
242Clinical Gastroenterology, 2008, 22, 209-224.10314243Optimal Screening Intervals for Individuals with a Family History of Colorectal Cancer. Gastrointestinal Endoscopy, 2008, 67, A5236.0.50244Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut, 2008, 57, 1330-1330.6.115245A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut, 2008, 57, 1539-1544.6.133246Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. American Journal of Gastroenterology, 2008, 103, 1505-1509.0.221247Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848.1.04248A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492.1.132249Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Castroenterology, 2007, 42, 66-71.0.838250Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology, 2007, 19, 878-882.0.838250The use of genetic testing in hereditary colorectal cancer syndromes; genetic testing in HNPCC, (A)FAP0.838	241	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2008, 22, 207-208.	1.0	3
243 Gastrointestinal Endoscopy, 2008, 67, AB236. 0.5 0 244 Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut, 2008, 57, 1330-1330. 6.1 15 245 A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Gut, 2008, 57, 1539-1544. 6.1 33 246 Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. American Journal of Gastroenterology, 2008, 103, 1505-1509. 0.2 21 247 Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848. 1.0 4 248 A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492. 1.1 32 249 Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 66-71. 0.6 16 250 Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology, 2007, 19, 878-882. 0.8 38 250 The use of genetic testing in hereditary colorectal cancer syndromes; genetic testing in HNPCC, (A)FAP 0.8 38	242		1.0	314
245A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic6.133246Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. American Journal of Gastroenterology, 2008, 103, 1505-1509.0.221247Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848.1.04248A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492.1.132249Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 66-71.0.616250Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology, 2007, 19, 878-882.0.838	243		0.5	0
243setting. Gut, 2008, 57, 1539-1544.6.133246Sporadic Duodenal Adenoma and the Association With Colorectal Neoplasia: A Case-Control Study. American Journal of Gastroenterology, 2008, 103, 1505-1509.0.221247Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848.1.04248A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492.1.132249Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 66-71.0.616250Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology, 2007, 19, 878-882.0.838240The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP0.80.8	244	Crohn's-like enterocolitis associated with mycophenolic acid treatment. Gut, 2008, 57, 1330-1330.	6.1	15
246American Journal of Gastroenterology, 2008, 103, 1505-1509.0.221247Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848.1.04248A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492.1.132249Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 66-71.0.616250Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology and Hepatology, 2007, 19, 878-882.0.838240The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP0.616	245		6.1	33
248A Nationwide Survey Evaluating Adherence to Guidelines for Follow-up After Polypectomy or Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492.1.132249Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 66-71.0.616250Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology, 2007, 19,0.838250The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP0.00.0	246		0.2	21
248 Treatment for Colorectal Cancer. Journal of Clinical Gastroenterology, 2008, 42, 487-492. I.I 32 249 Attendance at surveillance endoscopy of patients with adenoma or colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 66-71. 0.6 16 250 Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology, 2007, 19, 878-882. 0.8 38 250 The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP 0.8 0.8	247	Colon tumors and colonoscopy. Endoscopy, 2008, 40, 843-848.	1.0	4
249 Journal of Gastroenterology, 2007, 42, 66-71. 0.6 16 250 Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. European Journal of Gastroenterology and Hepatology, 2007, 19, 0.8 0.8 38 250 The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP 0.8 38	248		1.1	32
 in screening for colorectal cancer. European Journal of Gastroenterology and Hepatology, 2007, 19, 0.8 38 878-882. The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP 	249		0.6	16
The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP. Clinical Genetics, 2007, 72, 562-567.	250	in screening for colorectal cancer. European Journal of Gastroenterology and Hepatology, 2007, 19,	0.8	38
	251	The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP. Clinical Genetics, 2007, 72, 562-567.	1.0	29

Review article: detection and management of hereditary nonâ \in polyposis colorectal cancer (Lynch) Tj ETQq0 0 0 rg $\frac{1}{2}$ Overlogk 10 Tf 50

#	Article	IF	CITATIONS
253	Population Screening for Colorectal Cancer: Faeces, Endoscopes or X-Rays?. Analytical Cellular Pathology, 2007, 29, 185-194.	0.7	7
254	Risk Analyses for Sigmoidoscopy As a Screening Tool Based On the Incidence of Proximal Colorectal Carcinomas in a General Hospital. Gastrointestinal Endoscopy, 2006, 63, AB217.	0.5	0
255	Chromosomal Instability in MYH- and APC-Mutant Adenomatous Polyps. Cancer Research, 2006, 66, 2514-2519.	0.4	62
256	Attendance at Surveillance Endoscopy in Patients with Adenoma or Colorectal Cancer. Gastrointestinal Endoscopy, 2005, 61, AB261.	0.5	0
257	Outcome of Peptic Ulcer Bleeding, Nonsteroidal Anti-inflammatory Drug Use, and Infection. Clinical Gastroenterology and Hepatology, 2005, 3, 859-864.	2.4	62
258	Peptic Ulcer Bleeding, NSAID Use and Helicobacter Pylori Infection: A Prospective Study Evaluating Prevalence and Outcome. Gastrointestinal Endoscopy, 2004, 59, P152.	0.5	0
259	Response:. Gastrointestinal Endoscopy, 2004, 60, 494-495.	0.5	0
260	Lack of accuracy of the noninvasive stool antigen test in patients with gastroduodenal ulcer bleeding. American Journal of Gastroenterology, 2003, 98, 798-801.	0.2	8
261	Title is missing!. American Journal of Gastroenterology, 2003, 98, 1494-1499.	0.2	16
262	The role of endoscopic Doppler US in patients with peptic ulcer bleeding. Gastrointestinal Endoscopy, 2003, 58, 677-684.	0.5	34
263	Management of Bleeding Gastroduodenal Ulcers. Digestive Surgery, 2002, 19, 99-104.	0.6	4
264	Helicobacter pylori infection in peptic ulcer haemorrhage. Alimentary Pharmacology and Therapeutics, 2002, 16, 66-78.	1.9	36
265	The role of acid suppressants in upper gastrointestinal ulcer bleeding. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2001, 15, 463-475.	1.0	4
266	Management in Peptic Ulcer Hemorrhage:A Dutch National Inquiry. Endoscopy, 2000, 32, 935-942.	1.0	11
267	4702 National survey of management in peptic ulcer hemorrhage Gastrointestinal Endoscopy, 2000, 51, AB208.	0.5	0
268	Method for Estimating Bulk Density of Softâ€Bottom Sediment Cores. Journal of Environmental Quality, 1998, 27, 243-244.	1.0	0
269	Functional sensibility of the hand in leprosy patients. Leprosy Review, 1997, 68, 25-37.	0.1	8
270	Reference values for touch sensibility thresholds in healthy Nepalese volunteers. Leprosy Review, 1996, 67, 28-38.	0.1	26